Literature DB >> 24337069

Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing.

Martin Hart1, Elke Nolte, Sven Wach, Jaroslaw Szczyrba, Helge Taubert, Tilman T Rau, Arndt Hartmann, Friedrich A Grässer, Bernd Wullich.   

Abstract

UNLABELLED: MicroRNAs (miRNA) posttranscriptionally regulate gene expression and are important in tumorigenesis. Previous deep sequencing identified the miRNA profile of prostate carcinoma versus nonmalignant prostate tissue. Here, we generated miRNA expression profiles of prostate carcinoma by deep sequencing, with increasing tumor stage relative to corresponding nonmalignant and healthy prostate tissue, and detected clearly changed miRNA expression patterns. The miRNA profiles of the healthy and nonmalignant tissues were consistent with our previous findings, indicating a high fidelity of the method employed. In the tumors, quantitative real-time PCR (qRT-PCR) analysis of 40 paired samples of prostate carcinoma versus normal tissue revealed significant upregulation of miR-20a, miR-148a, miR-200b, and miR-375 and downregulation of miR-143 and miR-145. Hereby, miR-375 increased from normal to organ-confined tumors (pT2 pN0), slightly decreased in tumors with extracapsular growth (pT3 pN0), but was then expressed again at higher levels in lymph node metastasizing (pN1) tumors. The sequencing data for miR-375 were confirmed by Northern blotting and qRT-PCR. The regulation for other selected miRNAs could, however, not be confirmed by qRT-PCR in individual tumor stages. MiR-200b, in addition to miR-200c and miR-375 reduced the expression of SEC23A. Interestingly, miR-375, found by sequencing in pT2 upregulated by us and others in tumor versus normal tissue, and miR-15a, found by sequencing in pT2 and pT3 and in the metastasizing tumors, target the phosphatases PHLPP1 and PHLPP2, respectively. PHLPP1 and PHLPP2 dephosphorylate members of the AKT family of signal transducers, thereby inhibiting cell growth. Coexpression of miR-15a and miR-375 resulted in downregulation of PHLPP1/2 and strongly increased prostate carcinoma cell growth. IMPLICATIONS: These genomic data reveal relevant miRNAs in prostate cancer that may have biomarker and therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337069     DOI: 10.1158/1541-7786.MCR-13-0230

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  42 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

2.  Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

Authors:  C Coarfa; W Fiskus; V K Eedunuri; K Rajapakshe; C Foley; S A Chew; S S Shah; C Geng; J Shou; J S Mohamed; B W O'Malley; N Mitsiades
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

3.  Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis.

Authors:  Giovanni Lugli; Yachana Kataria; Zachary Richards; Peter Gann; Xiaofeng Zhou; Larisa Nonn
Journal:  J Vis Exp       Date:  2015-11-26       Impact factor: 1.355

Review 4.  The DNA damage response: the omics era and its impact.

Authors:  Kasper W J Derks; Jan H J Hoeijmakers; Joris Pothof
Journal:  DNA Repair (Amst)       Date:  2014-04-30

5.  An estimate of the total number of true human miRNAs.

Authors:  Julia Alles; Tobias Fehlmann; Ulrike Fischer; Christina Backes; Valentina Galata; Marie Minet; Martin Hart; Masood Abu-Halima; Friedrich A Grässer; Hans-Peter Lenhof; Andreas Keller; Eckart Meese
Journal:  Nucleic Acids Res       Date:  2019-04-23       Impact factor: 16.971

Review 6.  Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.

Authors:  Keith Richard Mitchelson; Wen-Yan Qin
Journal:  World J Biol Chem       Date:  2015-08-26

Review 7.  Prostasomes as a source of diagnostic biomarkers for prostate cancer.

Authors:  Carla Zijlstra; Willem Stoorvogel
Journal:  J Clin Invest       Date:  2016-04-01       Impact factor: 14.808

Review 8.  Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?

Authors:  Maria Schubert; Kerstin Junker; Joana Heinzelmann
Journal:  J Cancer Res Clin Oncol       Date:  2015-12-12       Impact factor: 4.553

9.  Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.

Authors:  Q Sheng; Y Zhang; Z Wang; J Ding; Y Song; W Zhao
Journal:  Clin Exp Immunol       Date:  2019-12-27       Impact factor: 4.330

10.  Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.

Authors:  Petra Leidinger; Martin Hart; Christina Backes; Stefanie Rheinheimer; Bastian Keck; Bernd Wullich; Andreas Keller; Eckart Meese
Journal:  Tumour Biol       Date:  2016-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.